Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy

European Journal of Ophthalmology

Volumn 21, Issue 4, 2011, Pages 440-445

  Cornish, Kurt Spiteri ^a   Williams, Graeme J ^a   Gavin, Michael P ^a   Imrie, Fraser R ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Avastin; Bevacizumab; Choroidal neovascularization; Lucentis; Punctate inner choroidopathy; Ranibizumab

Indexed keywords

BEVACIZUMAB; PREDNISOLONE; RANIBIZUMAB;

ADULT; ARTICLE; CHOROID DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PUNCTATE INNER CHOROIDOPATHY; RETINA DETACHMENT; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UVEITIS, POSTERIOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79957828572     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2010.6117     Document Type: Article

References (19)

1. Perentes Y, Van Tran T, Sickenberg M, Herbort CP. Subretinal neovascular membranes complicating uveitis: frequency, treatments, and visual outcome. Ocul Immunol Inflamm 2005; 13: 219-24.
2. Levy J, Shneck M, Klemperer I, Lifshitz T. Punctate inner choroidopathy: resolution after oral steroid treatment and review of the literature. Can J Ophthalmol 2005; 40: 605-8.
3. Flaxel CJ, Owens SL, Mulholland B, Schwartz SD, Gregor ZJ. The use of corticosteroids for choroidal neovascularisation in young patients. Eye 1998; 12: 266-72.
4. Brown J Jr, Folk JC, Reddy CV, Kimura AE. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 1996; 103: 1100-5.
5. Shah SS, Schachat AP, Murphy RP, Fine SL. The evolution of argon laser photocoagulation scars in patients with the ocular histoplasmosis syndrome. Arch Ophthalmol 1988; 106: 1533-6.
6. Hawkins BS, Bressler NM, Bressler SB, et al, Submacular Surgery Trials Research Group. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I: ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9. Arch Ophthalmol 2004; 122: 1597-611.
7. Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001; 132: 794-6.
8. Leslie T, Lois N, Christopoulou D, Olson JA, Forrester JV. Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol 2005; 89: 147-50.
9. Rosenfeld PJ, Saperstein DA, Bressler NM, et al, Verteporfin in Ocular Histoplasmosis Study Group. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study. Ophthalmology 2004; 111: 1725-33.
10. Fong KC, Thomas D, Amin K, Inzerillo D, Horgan SE. Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy. Eye 2008; 22: 528-33.
11. Nolan A, Weiden MD, Thurston G, Gold JA. Vascular endothelial growth factor blockade reduces plasma cytokines in a murine model of polymicrobial sepsis. Inflammation 2004; 28: 271-8.
12. Gass JMD. Stereoscopic Atlas of Macular Disease: Diagnosis and Treatment, 4th ed. St. Louis: Mosby, 1997; 26-32.
13. Mansour AM, Arevalo JF, Ziemssen F, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2009; 148: 310-6.
14. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007; 143: 977-83.
15. Tran TH, Fardeau C, Terrada C, Ducos De Lahitte G, Bodaghi B, Lehoang P. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1685-92.
16. Parodi MB, Iacono P, Kontadakis DS, Zucchiatti I, Cascavilla ML, Bandello F. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. Arch Ophthalmol 2010; 128: 1100-3.
17. Fine HF, Zhitomirsky I, Freund KB, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina 2009; 29: 8-12.
18. Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JM Jr, Slakter JS. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008; 126: 941-5.
19. Mansour AM, Arevalo JF, Ziemssen F, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2009; 148: 310-316.